Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT201 for upper limb essential tremor
2021-001988-24Phase 2Completed
- Sponsor
- Merz
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of incobotulinumtoxinA in essential tremor (ET) (3 arms), sponsored by Merz. Primary endpoint: Change from baseline to Week 6 in maximum tremor amplitude at wrist level during the unilateral treatment period. Started Jul 2021; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on 2021-001988-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001988-24.